Compare AMTX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTX | MOLN |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 137.2M |
| IPO Year | 2023 | 2021 |
| Metric | AMTX | MOLN |
|---|---|---|
| Price | $1.16 | $3.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $13.38 | $10.11 |
| AVG Volume (30 Days) | ★ 686.6K | 2.1K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $44.09 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.18 | $3.51 |
| 52 Week High | $3.80 | $5.36 |
| Indicator | AMTX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 39.28 |
| Support Level | N/A | N/A |
| Resistance Level | $1.87 | $4.19 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.49 | 19.54 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.